Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-γ

Journal of Immunotherapy

Volumn 32, Issue 5, 2009, Pages 524-538

  Knippertz, Ilka ^a   Hesse, Andrea ^a   Schunder, Tanja ^a   Kämpgen, Eckhart ^a   Brenner, Malcolm K ^b   Schuler, Gerold ^a   Steinkasserer, Alexander ^a   Nettelbeck, Dirk M ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

CD40L; Human dendritic cells; IL 12; Migration; Vaccination

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; DENDRITIC CELL VACCINE; INTERLEUKIN 12P70; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MELAN A; PROSTAGLANDIN E2; RECOMBINANT GAMMA INTERFERON;

ARTICLE; CD8+ T LYMPHOCYTE; CELL LEVEL; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL;

ADENOVIRIDAE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL MOVEMENT; CHEMOKINE CCL19; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; TH1 CELLS; TRANSDUCTION, GENETIC;

EID: 67651149582     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181a28422     Document Type: Article

References (53)

1. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
2. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21:873-886.
3. Oh ST, Kim CH, Park MY, et al. Dendritic cells transduced with recombinant adenovirus induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine. 2006;24:2860-2868.
4. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 2001;22:102-107.
5. Gaydos CA, Gaydos JC. Adenovirus vaccine. In: Orenstein WA, ed. Vaccines. 4th ed. Philadelphia: Saunders; 2004: 863-885.
6. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science. 2004;303:333.
7. Kochanek S. High-capacity adenovirus vectors for gene transfer and somatic gene therapy. Hum Gene Ther. 1999; 10:2451-2459.
8. Smith C, Farrah T, Goodwin R. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell. 1994;76:959-962.
9. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922.
10. Roy M, Waldschmidt T, Aruffo A, et al. The regulation of the expression of gp39, the CD40 ligand on normal and cloned CD4 T cells. J Immunol. 1993;151:2497-2510.
11. Grewal I, Flavell R. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
12. Dutton RW, Brandly LM, Swain SL. T cell memory. Annu Rev Immunol. 1998;16:201-223.
13. Najafian N, Khoury SJ. T cell costimulatory pathways: blockade for autoimmunity. Expert Opin Biol Ther. 2003;3: 227-236.
14. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40L on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184:747-752.
15. + T-helper and a T-killer cell. Nature. 1998;393:474-478.
16. Brunda MJ. Interleukin-12. J Leukoc Biol. 1994;55:280-288.
17. Trinchieri G, Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today. 1994;15: 460-463.
18. Trinchieri G. Interleukin-12: a cytokine produced by antigenpresenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84:4008-4027.
19. Moodycliffe AM, Shreedhar V, Ullrich SE, et al. CD40-CD40 ligand interactions in vivo regulate migration of antigenbearing dendritic cells from the skin to the draining lymph nodes. J Exp Med. 2000;191:2011-2020.
20. Ohl L, Mohaupt M, Czeloth N, et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 2004;21:279-288.
21. Dieu MC, Vanbervliet A, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in anatomic sites. J Exp Med. 1998;188:373-386.
22. Barratt-Boyes SM, Zimmer MI, Harshyne LA, et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol. 2000;164:2487-2495.
23. Scandella E, Men Y, Legler DF, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells require prostaglandin E2. Blood. 2003;103:1595-1601.
24. Adema GJ, de Vries JM, Punt CAJ, et al. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol. 2005;17:170-174.
25. Kalinski P, Vieira PL, Schuitemaker JHN, et al. Prostaglandin E2 is a selective inducer of interleukin-12p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001;97:3466-3469.
26. Iwasaki K, Noguchi K, Endo H, et al. Prostaglandin E2 downregulates interleukin-12 production through EP4 receptors in human monocytes stimulated with lipopolysaccharide from Actinobacillus actinomycetemcomitans and interferon-g. Oral Microbiol Immunol. 2003;18:150-155.
27. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142.
28. Luft T, Jefford M, Luetjens P, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood. 2002;100:1362-1372.
29. Luft T, Maraskovsky E, Schnurr M, et al. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood. 2004;104:1066-1074.
30. Takahashi S, Rousseau RF, Yotuda P, et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001;12:659-670.
31. He TC. Adenoviral vectors. Curr Protoc Hum Genet. 2004; Mai: 12.4.1-12.4.25.
32. Prechtel AT, Turza NM, Kobelt DJ, et al. Infection of mature dendritic cells with herpes simplex virus type 1 dramatically reduces lymphoid chemokine-mediated migration. J Gen Virol. 2005;86:1645-1657.
33. Schaft N, Doerrie J, Thumann P, et al. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol. 2005;174:3087-3097.
34. Caux C, Massacrier C, Vanbervliet A, et al. Activation of human dendritic cells through CD40 cross-signalling. J Exp Med. 1994;180:1263-1272.
35. Browne SK, Roessner JR, Zhu SZ, et al. Differential IFNgamma stimulation of HLA-A gene expression through CRM-1-dependent nuclear RNA export. J Immunol. 2006;177: 8612-8619.
36. Snijders A, Kalinski P, Hilkens CM, et al. High-level IL-12 production by dendritic cells requires two signals. Int Immunol. 1998;10:1593-1598.
37. Alder J, Hahn-Zoric M, Andersson BA, et al. Interferongamma dose-dependently inhibits prostaglandin E2-mediated dendritic-cell-migration towards secondary lymphoid organ chemokines. Vaccine. 2006;24:7087-7094.
38. Calderhead DM, DeBenedette MA, Ketteringham H, et al. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J Immunother. 2008;31:731-741.
39. Bonehill A, Tuyaerts S, Van Nuffel AMT, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008;16:1170-1180.
40. + T cells and is quickly expressed on the cell surface in an antigen specific manner. Blood. 2007;110:2520-2527.
41. Lesley R, Kelly LM, Xu Y, et al. Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival. Proc Natl Acad Sci USA. 2006;103:10717-10722.
42. Yellin MJ, Sippel K, Inghirami G, et al. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40L. J Immunol. 1994;152: 598-608.
43. Vieira PL, De Jong EC, Wierenga EA, et al. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000;164:4507-4512.
44. Tcherepanova IY, Adams MD, Feng X, et al. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol. 2008;9:90.
45. Dauer M, Lam V, Arnold H, et al. Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J Immunol Methods. 2008;337:97-105.
46. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
47. Randolph GJ, Sanchez-Schmitz G, Angeli V. Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances. Springer Semin Immunopathol. 2005;26:273-287.
48. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. Alphatype-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64: 5934-5937.
49. Tillman JA, de Gruijl TD, Luykx-de Bakker SA, et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol. 1999;162:6378-6383.
50. Bekousova N, Korokhov N, Krendelshchikova V, et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol. 2003;77:11367-11377.
51. Contursi C, Wang JM, Gabriele L, et al. IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFN-gamma-responsive promoters in macrophages. Proc Natl Acad Sci U S A. 2000;97:91-96.
52. Khorana AA, Rosenblatt JD, Sahasrabudhze DM, et al. A phase I trial of immunotherapy with intratumoral adenovirusinterferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther. 2003;10:251-259.
53. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. 2006; 13:830-844.